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Abstract
Meningiomas are the most common primary intracranial tumors in the adult popula‐
tion [1]. They are generally considered benign lesions but after the 2007 WHO classifica‐
tion, the proportion of atypical meningiomas has steeply increased. Surgery is considered
the mainstay of the treatment and a complete resection is considered curative in WHO
grade I meningiomas. The role of adjuvant treatments like radiotherapy (stereotactic
radiosurgery or conventional external beam irradiation) and chemotherapy in more
aggressive cases is still discussed, above all in WHO grade II meningiomas. We would
like to expose the most important advances in meningiomas’ management in accord‐
ance with the recent literature evidences.
Keywords: meningioma, management, benign meningiomas, atypical meningioma,
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1. Introduction
Meningiomas are the most common primary intracranial tumors[1]. Their origin from the
arachnoid layer was first hypothesized by John Cleland in 1864 [2] and then reasserted by
Cushing and Weed in 1915 [3]. Meningiomas are classified according to their dural attach‐
ment and histological grading. The 2000 WHO histological classification has been modified in
2007,  and the epidemiology of  more aggressive subtypes has thus recently changed [4].
Meningiomas may be incidental and asymptomatic, or they may present clinically with focal
neurological deficit in accordance with a mass effect on an eloquent area or with epileptic seizures.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Surgery represents the mainstay of the treatment, but the management of more aggressive
meningioma is challenging. The role of adjuvant therapies should thus be discussed in cases of
more aggressive histological types, subtotal resection and recurrent diseases.
2. Epidemiology
Meningiomas account for 20 and 38% of all primary intracranial tumors, respectively, in males
and in females, with an incidence of about five cases per 100,000 persons [5]. In an autoptic
series about 2–3% of the general population had an incidental asymptomatic meningioma [6].
The female sex and estrogenic conditions seem to be a risk factor for developing meningio‐
mas, with a female to male ratio of about 3:1 [7].
Hormonal therapy and hormone-dependent conditions such as breast cancer [8], pregnancy
[9], or obesity [10] were in fact associated with a higher incidence of meningiomas. Cranial
irradiation is also a recognized risk factor for developing meningiomas, usually with tumors
having a more complex cariotype and a more aggressive behavior [11]. Head traumas have
been for long associated with a higher meningioma incidence, but the causal effect was never
demonstrated.
Some genetic conditions may favor the arising of meningiomas, such as neurofibromatosis
type 2 (NF2), an autosomal dominant disorder characterized by mutation of the tumor
suppressor gene NF2 coding for merlin in chromosome 22q12.2. Also multiple endocrine
neoplasia type 1 (MEN1) is associated to a higher incidence of meningioma.
Meningiomas may derive from the dura of the cranial vault, of the skull base and at sites of
dura reflection like the falx, the tentorium, and the dura recovering venous sinuses.
Meningiomas may also arise from the optic-nerve sheath and from the choroid plexus.
About 10% of them arise in the spine. In rare cases, meningiomas outside the craniospinal axis
have been reported [12]. The preferential localization of intracranial meningiomas is summar‐
ized in Figure 1.
Figure 1. Graphic representation of the topographic distribution of intracranial meningiomas.
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According to the 2007 World Health Organization (WHO) classification, meningiomas are
divided in three categories: grade I or benign meningiomas, grade II or atypical meningio‐
mas, and grade III or anaplastic meningiomas [11]. With this new grading system, which
includes the brain invasion into the diagnostic criteria for aggressiveness, the percentage of
atypical meningiomas grew to 20–35% of newly diagnosed meningiomas [13]. This classifica‐
tion is important because, together with the extension of resection, it may help in predicting
the recurrence rate and thus the global prognosis [14, 15] (Figure 2).
Figure 2. The recurrence rate at 5 years was stratified according to literature data: The recurrence after surgery is strict‐
ly related to the histologic grade of the lesion (WHO classification).
3. Clinical presentation
In many cases, meningiomas are asymptomatic and discovered in the context of investiga‐
tions of unrelated symptoms [16]. When symptomatic they may determine epileptic seizures
or focal neurological deficit according to the irritation or the compression of eloquent areas or
vasculo-nervous structures. Hydrocephalus may be secondary to meningiomas obstructing
the physiologic CSF flow. An increased intracranial pressure may be present in cases of
voluminous lesions or with an associated peritumoral edema.
Focal neurological deficit is directly linked to the localization of the tumor, according to the
compression of cranial nerves or specific hemispheric regions. Spinal tract compression is also
typical for spinal meningiomas.
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4. Radiology
Meningiomas present as well-defined extra-axial lesions with a typical peripheral CSF cleft.
They present a homogeneous contrast enhancement on CT- and T1-weighted MRI with
gadolinium administration. The tumor has a dural or bone implantation and a typical dural
tail (contrast enhancement of the dura adjacent to meningioma implantation) (Figures 3 and
4). A reactive sclerosis of the underlying bone may be present in about half of skull-base
meningiomas [17]. In rare cases, bone erosion is present (Figure 5). Calcifications or cystic
portions may be present. Hyperintensity in T2-weighted MRI may denote a higher water
content and thus an easily resectability during surgery.
Figure 3. T1-weighted coronal (a) and axial (b) MRI with gadolinium administration showing a well-defined extra-ax‐
ial lesion with an homogeneous enhancement and a contiguous dural enhancement (dural tail). A subtle CSF cleft is
also visible between the lesion and the cerebral surface. These radiologic findings are typical for a convexitary menin‐
gioma.
Figure 4. A tentorial meningiomas with less demarcated limits and probably infiltrating the adjacent brainstem. The
dural tail is evident in this T1-weighted MRI post gadolinium administration. This 33-year-old patient was irradiated
during infancy after the resection of an ependymoma of the IVth ventricle. This may help in explaining the atypical
features of the lesion.
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Figure 5. This skull base meningioma completely eroded the skull base and encased the internal carotid artery on the
left side. Also the vertebral artery was surrounded by the tumor (not shown). The anatomy was completely modified
by the lesion, and a preoperative study of the images was essential to plan the surgery.
Meningiomas may present an associated venous invasion and MRI venography may help in
evaluating sinus thrombosis in the preoperative period.
An angiography may be performed in the preoperative period to assess the vascularization of
the lesion and the relationship with important vascular structures. Meningiomas are in most
of cases vascularized by the meningeal artery supplying the meninges at the tumor sites, and
the angiographic blush is also called mother-in-law blush, because it comes early and leaves
late. However, because of the risks linked to this invasive procedure, it is often performed in
the context of the planning of a preoperative embolization.
5. Genetic and molecular profiles
More than a half of sporadic meningiomas of every histological grade have a mutation in NF2
gene on the chromosome 22q12, coding for merlin (moesin–ezrin–radixin-like protein), and it
is considered an early event in tumorigenesis [18]. Merlin seems to interact with trans-
membranous proteins to activate pathways promoting cell proliferation. Its expression may
vary, however, according to meningioma’s subtype [19]. The product of the DAL-1 gene, a
member of the protein 4.1 family, has also been supposed to be implicated in meningioma
tumorigenesis and progression. The prevalence of mutations of protein 4.1B was not differ‐
ent among WHO grades, and it may be an early event in meningioma tumorigenesis [20].
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Aside 22q deletions, multiple genetic mutations are observed in meningioma progression, such
as loss of heterozygosis in 1p, 3p, 6q, 9p, 10q, and 14q [21] and are associated with histologi‐
cal progression [22].
Recently, the analysis of microRNAs (miRNAs) profiles was identified as a potential tool to
define the natural history of different meningiomas. A low expression of miR-29c-3p and
miR-219-5p was associated with more aggressive phenotypes and with a higher risk of
recurrence [23]. On the contrary, high expression of miR-145 seems to be associated with a
more indolent biological behavior.
Complex cariotypes were found in 34% of benign meningiomas, 45% of atypical, and 70% of
anaplastic meningiomas [24].
Proliferative markers such as MIB-1 and Ki67 have been associated with a more aggressive
biological behavior in some studies [25, 26]. The relationship between genetic and molecular
alterations and recurrence is a matter of debate: According to Sandberg et al. [26], the
recurrence rate seems to be associated to proliferative markers and Ki-67 and cyclin B1 genes
were overexpressed in recurrent meningiomas [27, 28], with a significant association be‐
tween Ki-67 and tumor recurrence [29]. Contrasting results exist, however, on this argument,
as Aguiar et al. [30] did not find any association between MIB-1 and the histological grade.
Other markers have also been investigated, such as p53, TGFalpha, and beta, PDGF [25, 31].
EGFRs are overexpressed in about 60% of meningiomas, while VEGF is also upregulated in
meningioma cells but no association with the WHO histological grade was observed [32]. The
invasiveness of meningioma cells has been linked to the expression of matrix-metalloprotei‐
nase-9 (MMP-9), and its expression may be a prognostic marker for recurrence [33].
In 1979, Donnell et al. [34] were the first to describe the role of estrogen receptors in meningi‐
omas development. However, over the time, progesterone receptors showed to have a higher
expression in meningioma cells and their level was correlated to a favorable clinical behav‐
ior [35]. Also the expression of E-cadherin was more elevated in benign meningiomas [36].
Furthermore, about 70–100% meningiomas express somatostatin receptors, predominantly the
type 2a (hsst2a) [37].
6. Benign meningiomas or WHO grade I meningiomas
In most of cases, WHO grade I meningiomas are diagnosed. They present a benign clinical
course, with rare mitoses and occasional pleomorphic nuclei. Various architectural patterns
have been described, whose most frequent are meningothelial, fibroblastic, and transitional
meningiomas. Meningothelial or syncytial meningiomas are characterized by a high cellular
density with cells disposed in packed sheets. Fibroblastic meningiomas are similar to schwan‐
nomas, with elongated cells. Cellular whorls and psammoma bodies (mineralized whorls) are
most common in the transitional type, which present intermediate features between the
meningothelial and the fibroblastic subtype. Other rare variants are the psammomatous
meningiomas, characterized by multiple psammoma bodies, the angiomatous meningiomas,
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which are extremely vascularized with scarce foci of meningothelial cells and the secretory
meningiomas, with lumina formed by cytokeratin-immunoreactive cells and containing PAS
positive material.
Benign meningiomas are considered cured, if a complete resection is performed. Thus, a simple
surveillance is indicated in cases where a gross total resection is possible (Simpson grade 1
or 2) with serial cerebral MRI, without any complementary treatment. A very small portion of
benign meningiomas progresses to more aggressive variants (<2%) [38], but when consider‐
ing only recurrent tumors, the prevalence becomes significantly higher (14%) [39]. The clinical
behavior and the malignant potential of meningioma are still matter of debate. Many au‐
thors applied the model of clonal progression to meningiomas with a progressive appear‐
ance of more aggressive cellular subpopulations according with the presence of genetic
imbalances and molecular modifications [40, 41].
Meningiomas show immunohistochemical positivity for epithelial membrane antigen (EMA)
in 80% of cases. They also express other epithelial markers such as vimentin and cytokeratin.
Antileu 7 and glial fibrillary acidic protein (GFAP) stains, characteristics for schwannomas and
gliomas, respectively, are uniformly negative. Immunohistochemistry may thus help in the
differential diagnosis in difficult cases.
An elevated labeling for Ki-67 may denote a more aggressive lesion [42, 43].
7. Atypical meningiomas or WHO grade II
According to the WHO classification of 2007, a growing subset of lesions (about one third) has
the histopathological characteristics to be defined atypical, thus showing a more aggressive
behavior [13].
The criteria to define atypical meningiomas are independent from meningioma subtype.
Atypical meningiomas are in fact described as lesions with one or more of these characteristics:
- 4–19 mitoses per 10 high power fields (hpf) and/or brain invasion and/or at least three of the
following features:
• necrosis
• macronucleoli
• loss of ordered architecture
• hypercellularity
• small cells
Four subtypes of WHO grade II meningiomas have been described [11]: The chordoid
meningioma is histologically similar to chordoma, with a mucin-rich stroma and clear vacuoles
in epithelioid cells. This pattern is mixed with meningothelial or transitional tumor areas, and
it is usually supratentorial. Castleman’s disease has been reported in association with this
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subtype [44]. The clear cell meningioma is composed by cells with glycogen-rich clear
cytoplasm and extensive collagen deposition. This subtype typically occurs in the cauda equina
region and in the posterior fossa. A high recurrence rate is characteristics. The atypical
meningioma has atypical features and cannot be classified as chordoid or clear cell meningi‐
oma.
An association between the survival rate and the extent of resection for atypical meningio‐
mas was confirmed by multiple studies [45, 46]. Even if a maximal resection is the first aim of
the surgery, these lesions are often less well delimited and a safe resection is often incom‐
plete because of bone infiltration and vascular invasion. Many studies are actually investigat‐
ing the real role of adjuvant therapies. If fact both radiotherapy and eventually chemotherapy
are not free of side effects and even if they are commonly adopted for malignant meningio‐
mas, the balance benefits–risks is not yet assessed for atypical meningiomas.
8. Anaplastic or malignant meningiomas or WHO grade III
Anaplastic meningiomas may present directly as primary tumors or may derive from a
malignant transformation of less aggressive lesions. Malignant meningiomas are character‐
ized by the following [4]:
- 20 or more mitoses/10 hpf
- predominant rhabdoid or papillary morphology
Papillary meningiomas are rare and commonly found in children, characterized by a pseudo‐
papillary architecture. Rhabdoid meningiomas are formed by cells with eccentric nuclei and
paranuclear inclusions.
Anaplastic meningiomas are associated with a high risk of recurrence and distant metasta‐
ses. The most common sites of extraneural metastases are the liver, lungs, pleura, and lymph
nodes.
Surgery aiming to obtain gross total or near total surgical resection represents the first choice,
and it is combined with different types of external beam radiotherapy (fractionated or
stereotactic radiosurgery) [47, 48] Anaplastic meningiomas are malignant tumors with a
survival limited to 1.5–3.5 years according to most of the series [49]. A better overall survival
was observed in cases <60 years old and in patients receiving adjuvant radiotherapy [46]. The
role of chemotherapic agents is still under investigation, and the debate is open in particular
for somatostatine analogues [50, 51].
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9. Management
9.1. Surgery
The mainstay of the treatment for symptomatic or enlarging meningiomas of every histolog‐
ical grade is the surgical excision. A complete surgical excision of the tumor and of the
surrounding dural attachment is recommended and may be curative. Furthermore surgery
allows a pathological diagnosis, may improve the symptoms, and relieve the mass effect. The
extent of surgical resection was first classified by Simpson [52], and it is strongly associated to
the recurrence rate (Table 1). The term “Simpson grade 0” was also coniated, to define a total
resection of the tumor, of the infiltrated dura and of the hyperostotic bone, with a 2 cm of free
margins [53]. A complete resection (Simpson I) may not always be performed because of the
localization/size of the tumor and their relationship with neurovascular structures. Thus, the
highest recurrence rate was described in patients with sphenoid wing meningiomas, fol‐
lowed by parasagittal meningiomas. En plaque meningiomas, with a flat extension in the
subdural space, may also be difficult to resect completely. However, according to a recent
study, patients with skull base meningiomas present at a younger age and lesions have often
a more indolent behavior [54].
Simpson grade Extent of resection Recurrence rate at 5 years
0 Total removal of the tumor, dural attachment, and infiltrated bone
with additional resection of a 2-cm dural margin
0%
1 Total removal of the tumor, dural attachment, and infiltrated bone 9%
2 Total removal of the tumor, dural attachment coagulated 19%
3 Total removal of the tumor, without resection nor
coagulation of the dura/infiltrated bone
29%
4 Partial resection of the tumor 39%
5 Decompression (biopsy) Ns
Modified according to Kinjo et al. [53].
Table 1. Simpson grade classifying the extent of resection for meningiomas.
More aggressive meningiomas may present with associated brain invasion, venous sinuses
invasion or less defined limits, thus rendering the complete resection more challenging. The
minimization of postoperative neurological deficit is one of the main goals of neurosurgeons,
thus respecting neurovascular structures and the extent of resection should be balanced with
the risk of postoperative disability. In the most complex cases, thus, a subtotal resection may
be performed and a residue is left in place, which will be followed or treated with adjuvant
radiotherapy, as fractionated external beam or stereotactic radiotherapy.
Meningiomas’ Management: An Update of the Literature
http://dx.doi.org/10.5772/62929
369
The extent of resection being a key predictor of recurrence, a long-term follow-up is essen‐
tial, especially in cases of subtotal resection.
9.2. Radiotherapy
Radiotherapy has been advocated as primary therapeutic option in cases, where the surgical
excision was judged too risky because of the considerable postoperative neurological mor‐
bidities or as complementary treatment after surgery [55]. Several options of radiation
therapies are available to treat meningiomas, such as photon-based stereotactic radiosurgery
and hypofractionated radiation therapy. Positive results with radiation therapy have been
observed in cases of incomplete resection [56, 57] or recurrence [58].
Furthermore interesting results have been found with cavernous sinus meningiomas [59] or
parasagittal meningiomas [60] involving the posterior third of the superior sagittal sinus.
Patients treated with a combined approach (subtotal resection followed by stereotactic
radiosurgery) experienced a progression-free survival similar to the subgroup where GTR was
achieved.
To summarize the most recent literature evidences, the adjuvant use of radiotherapy after the
resection of grade III meningiomas is well established, while it is still matter of debate after
gross total resection of grade II meningiomas. Aghi et al. [61] showed how immediate adjuvant
radiation therapy may improve overall survival and reduce local recurrence with atypical
meningiomas. However, no randomized controlled or prospective studies exist and the level
of evidence is thus low. Some authors suggest in fact that a close follow-up is sufficient after
GTR of atypical meningiomas, thus avoiding the risk of side effects of radiotherapy. Sun et
al. [47] suggested that the analysis of histopathological features of aggressiveness, such as brain
invasion and the MIB-1 index, to decide of a complementary treatment should be administered.
A dose of 60 Gy is generally considered beneficial for fractionated radiotherapy after subto‐
tal resections and many centers administer hypofractionated radiotherapy, with doses of 1, 8,
or 2 Gy per fraction, to diminish the risk of long-term neurotoxicity. After gross total resec‐
tions, some authors suggest the possibility to lower the doses to 54 Gy (RTOG trial N°0539).
The EORTC trial N°22042-26042 is actually investigating the benefit of 60 Gy after GTR, with
an additional boost of 10 Gy after STR. The same doses seem to be advantageous with proton-
beam therapy [62].
Further indications for radiation therapy are as follows: As adjuvant treatment after the
incomplete resection of a meningioma or with recurrent tumors whose surgical removal of the
residue will bring important potential neurological morbidities or with inoperable lesions.
The limitation of fractionated radiotherapy and stereotactic radiosurgery are linked to the
tumor size and to the radiation neurotoxicity, with a risk of necrosis, cerebral edema and
damage of critical neurovascular structures with consequent cranial nerve palsy [48]. Recent
progresses in the field of conformational radiotherapy and stereotactic radiotherapy allow a
better definition of the target, thus limiting the dose to the normal tissue and delivering a more
focused dose on the resection bed/residual meningioma.
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Other radiation-induced complications described in literature are the risk of secondary
malignancy or of tumor progression [63, 64].
9.3. Chemotherapy
The development of new medical options for recurrent or aggressive meningiomas is strongly
dependent from progresses made in the understanding of molecular pathways. The role of
classic chemotherapic agents is disappointing [65]. Temozolomide showed no efficacy on
refractory meningiomas according to Chamberlain et al. [66], and its efficacy seems to be linked
to the functionality of the enzyme O6-methylguanine-DNA-methyltransferase [67]. Hydrox‐
yurea showed preliminary favorable results in recurrent and radiation refractory meningio‐
mas [68], but the study was conducted in a limited number of patients. The study of
Chamberlain et al. [69] on the contrary showed a limited efficacy. Contrasting results exist on
the efficacy of irinotecan on preclinical studies [70].
Multiple targeted therapies have been tried in preclinical and clinical trials. In the animal
model, the use of mTOR inhibitors such as temsirolimus and everolimus showed a reduced
growth rate in meningioma cells [71]. On the contrary, the application of EGFR inhibitors
(gefitinib and erlotinib) did not show a significant benefit in patients with refractory menin‐
giomas [72]. The most famous monoclonal antibody binding VEGFB, bevacizumab, was also
investigated by Lou et al. [73] in a population of recurrent/progressive meningiomas, and a
positive response was obtained in recurrent meningiomas. The benefit of this therapy was,
however, not clear in the study of Nunes et al. [74]. Two ongoing trials will evaluate the efficacy
of bevacizumab in a phase II trial (NCT01125046) and its association with everolimus in a
cohort of recurrent/progressive meningiomas (NCT00972335). In preclinical studies suniti‐
nib, a PDGFRB inhibitor may inhibit cellular migration in vitro [75]. Encouraging results from
the use of sunitinib were also obtained in a cohort of patients with malignant meningiomas [50].
Hormonal therapies have been widely investigated as cytostatic therapies after the discov‐
ery of the association between meningioma incidence and hyperestrogenic and hyperproges‐
tinic conditions [18]. Mifepristone (RU-486) is an antagonist of progesterone receptors, and it
is the most widely investigated agent in the oncologic field. Clinical studies on its efficacy
show, however, contrasting results [7, 76, 77], and only minor evidences exist to recommend
mifepristone with inoperable progressive meningiomas, after consideration of the histologi‐
cal grade of the tumor and progesterone receptor expression [78]. Positive preliminary results
were obtained with diffuse meningiomatosis [79].
Immunohistochemical studies showed a high prevalence of somatostatin receptor (SSTR)
expression in meningiomas, in particular of SSTR2A. The sandostatin LAR was tested in a
prospective trial including recurrent menngiomas, with a partial radiological response in one
third of patients [80]. However, pasireotide, an analogue with a wider affinity for multiple
subtypes of SSTR, showed no benefit in recurrent meningiomas [51].
In conclusion, up to date chemotherapeutic agents and hormonal therapies shows a limited
efficacy in the management of recurrent/progressive and more aggressive meningiomas and
the field of investigation remains large. The nanotechnology, combined with the most recent
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targeted therapies, may actually represent a revolution in the targeting, transport and
delivering of chemotherapeutic agents [81], thus opening new ways for the treatment of these
tumors.
10. Conclusions
Meningiomas were classically considered benign tumors. However, according to the new
WHO classification, the proportion of more aggressive variants has steeply increased and thus
the management has become more challenging. Surgery represents the mainstay of the
treatment and a complete resection may be considered curative in WHO grade I meningio‐
mas. However, neurosurgeons have often to deal with the risk of postoperative neurological
morbidities and the role of adjuvant treatments, such as radiotherapy and chemotherapy, after
subtotal resection or after the pathological confirmation of WHO grade II or III meningio‐
mas, is actually being defined. A huge literature dealing with adjuvant radiotherapy and new
cytostatic agents is developing, with the aim of obtaining an optimal long-term control. Up to
now, treatments are empirically based and many hopes reside in new prospective and
randomized controlled trials to better define the role of each therapeutic strategy and the best
way to combine them.
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